18+ · Research Use Only · Not for Human Consumption

Retatrutide · Phase 3 · Ongoing

TRIUMPH-OUTCOMES

TRIUMPH-OUTCOMES is a phase 3 trial of retatrutide in adults living with obesity (cardiovascular and kidney outcomes), registered as NCT06383390 and not yet reported (ClinicalTrials.gov, checked 23 September 2026).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Design

Trial design and sources

Compound
Retatrutide
Phase
3
Population
Adults living with obesity
Participants randomised
Not published
Duration
Not published
Primary endpoint
Cardiovascular and kidney outcomes
Estimand
Not stated in the source read
Read out
Not yet reported
  • ClinicalTrials.gov record, active, not recruiting open · checked 23 September 2026
  • Registry: NCT06383390

Questions

TRIUMPH-OUTCOMES, answered

What did TRIUMPH-OUTCOMES find?

TRIUMPH-OUTCOMES is a phase 3 trial of retatrutide in adults living with obesity (cardiovascular and kidney outcomes), registered as NCT06383390 and not yet reported (ClinicalTrials.gov, checked 23 September 2026).

When will TRIUMPH-OUTCOMES report?

TRIUMPH-OUTCOMES is active and not recruiting on ClinicalTrials.gov (NCT06383390); no results have been published. Checked 23 September 2026.